Market capitalization | $48.77m |
Enterprise Value | $33.00m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 47.83 |
P/S ratio (TTM) P/S ratio | 70.68 |
P/B ratio (TTM) P/B ratio | 2.35 |
Revenue growth (TTM) Revenue growth | -93.61% |
Revenue (TTM) Revenue | $690.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Collplant Holdings ADR forecast:
2 Analysts have issued a Collplant Holdings ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.69 0.69 |
94%
94%
|
|
Gross Profit | -2.54 -2.54 |
130%
130%
|
|
EBITDA | -17 -17 |
195%
195%
|
EBIT (Operating Income) EBIT | -18 -18 |
163%
163%
|
Net Profit | -17 -17 |
160%
160%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. The company's products include VergenixSTR, VergenixFG, and CollPlant Surgical Matrix. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.
Head office | Israel |
CEO | Yehiel Tal |
Employees | 75 |
Founded | 2004 |
Website | www.collplant.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.